Please provide your email address to receive an email when new articles are posted on . Vision outcomes using a port delivery system proved equivalent to ranibizumab injections and showed a positive ...
A deep learning model may be able to outperform ophthalmologists in predicting neovascular age-related macular degeneration (nAMD) recurrence. Recurrence of neovascular age-related macular ...
New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment intensity for underlying nAMD remained ...
Please provide your email address to receive an email when new articles are posted on . Physicians’ Education Resource ®, LLC, is accredited by the Accreditation Council for Continuing Medical ...
P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...
Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing durability as a primary unmet need in nAMD and DME management.
BARCELONA, Spain — Patients who receive a diagnosis of neovascular age-related macular degeneration (nAMD) from their primary care clinician may be less likely to adhere to treatment than those who ...
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III ...
Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape ...
Roche (RHHBY) announced new data from two studies on ophthalmology drug Vabysmo (faricimab). Vabysmo is already approved in several countries for people with neovascular or ‘wet’ age-related macular ...
Optometrists' ability to classify retinal lesions for re-treatment decisions regarding quiescent neovascular age-related macular degeneration (nAMD) is not inferior to that of ophthalmologists, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results